AD Pipeline Watch: Zai Lab’s IL-13/IL-31R Bispecific Antibody Shows Promise in Preclinical Pilot Study
Zai Lab’s interleukin (IL)-13/IL-31R bispecific antibody performed well in a pilot preclinical study presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, Scotland.